Adriamycin-induced nephropathy model 【Model update】

  • 2020.06.12

Update regarding chronic kidney disease (CKD) and the renewal of our Adriamycin-induced nephropathy (ADR) mouse model.


Chronic kidney disease (CKD) is a progressive loss in kidney function. 1 in 10 people have some degree of kidney disease and every year millions die prematurely of complications related to CKD.

About 1% of CKD patients progress to end-stage renal disease (ESRD), and it is reported that ESRD patients (who need dialysis or kidney transplantation) consume 6.7% of the total medicare budget to care for less than 1% of the covered population.

Therefore, early detection of chronic kidney disease and the development of therapeutic agents are required since there is no cure for CKD, although treatment can slow the progression of the disease and can prevent other serious conditions developing.


The ADR model is a well-characterized disease model for CKD and the advantages of SMC’s model are as below.

  1. Histological evaluation of glomerular and interstitial tubular disorders and fibrosis is possible.
  2. Useful for the assessment of early to mid-stage renal disease
  3.  Evaluation of prevention and treatment efficacy using Valproic acid (VPA) as a reference control

*: VPA is a histone deacetylase inhibitor that exhibits anti-cancer, anti-inflammatory and neuroprotective effects. It is known as an anticonvulsant drug.


In this model, pathological changes in urine and tissues seen in the early stages after kidney injury are mostly observed.

Therefore, we believe that this model will enable clients to analyze the early-to-mid stage of CKD, which is fundamental for the diagnosis and development of therapeutic drugs for the disease.

I have attached some information on the pathophysiology and drug efficacy data of our ADR model.


We have a variety of fibrotic and inflammatory disease models as well as the ADR model, through which we provide pharmacological efficacy testing services.